JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung CancersSean P. Pitroda(University of Chicago), Nikolai N. Khodarev(University of Chicago)Molecular Cancer TherapeuticsFebruary 21, 201810.1158/1535-7163.mct-17-0667Cited by 23SaveCiteExport RISWatch citationsRelated PapersLong-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.|Journal of Clinical Oncology|2023|8